Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Subcutaneous Concizumab Prophylaxis in Patients with Hemophilia A or B with Inhibitors: Efficacy and Safety Results By Hemophilia Subtype from the Phase 3 Explorer7 Trial

Melissa Frei-Jones, Katarina Cepo, Roseline d'Oiron, Ai Sim Goh, Mary Mathias, Jan Odgaard-Jensen

Blood (2022) 140 (Supplement 1): 466–468.

https://doi.org/10.1182/blood-2022-166522

Published: 2022

Journal Articles

How I manage pregnancy in women with Glanzmann thrombasthenia

Mathieu Fiore, Loïc Sentilhes, Roseline d’Oiron

Blood (2022) 139 (17): 2632–2641.

https://doi.org/10.1182/blood.2021011595

Published: 2022

Journal Articles

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, Christophe Schmitt, Cedric Hermans, Giuliana Ventriglia, Jerzy Windyga, Anna Kiialainen, Roseline d'Oiron, Paul Moorehead, Vanda Teodoro, Amy D. Shapiro, Johannes Oldenburg

Blood (2021) 138 (Supplement 1): 343.

https://doi.org/10.1182/blood-2021-146009

Published: 2021

Journal Articles

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Thierry Calvez, Hervé Chambost, Ségolène Claeyssens-Donadel, Roseline d’Oiron, Véronique Goulet, Benoît Guillet, Virginie Héritier, Vanessa Milien, Chantal Rothschild, Valérie Roussel-Robert, Christine Vinciguerra, Jenny Goudemand

Blood (2014) 124 (23): 3398–3408.

https://doi.org/10.1182/blood-2014-07-586347

Published: 2014

Includes: Supplemental data

Journal Articles

The International Prospective Glanzmann's Thrombasthenia Registry (GTR) Special Issues in Children

Rainer Zotz, MD, Giovanni di Minno, MD, Roseline d'Oiron, MD, Man-Chiu Poon, MD

Blood (2012) 120 (21): 3341.

https://doi.org/10.1182/blood.V120.21.3341.3341

Published: 2012

Journal Articles

The International Prospective Glanzmann's Thrombasthenia Registry (GTR). Special Issues in Women.

Roseline d'Oiron, MD, Man-Chiu Poon, MD, Rainer Zotz, MD, Giovanni di Minno, MD

Blood (2012) 120 (21): 2202.

https://doi.org/10.1182/blood.V120.21.2202.2202

Published: 2012

Journal Articles

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

Yohann Repesse, PhD, Ivan Peyron, Jordan Dimitrov, PhD, Suryasarathi Dasgupta, PhD, Elika Farrokhi Moshai, Annie Borel-Derlon, MD, PhD, Catherine Costa, MD, Benoist Guillet, MD, PhD, Roseline d'Oiron, MD, Achille Aouba, MD, Chantal Rothschild, MD, Johannes Oldenburg, MD, Ana Pavlova, MD, Srinivas Kaveri, D. V. M., Ph.D, Sebastien Lacroix-Desmazes, PhD

Blood (2012) 120 (21): 38.

https://doi.org/10.1182/blood.V120.21.38.38

Published: 2012

Journal Articles

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

Roseline d'Oiron, MD, Virginie Demiguel, MSc, Annie Borel-Derlon, MD, PhD, Ségolène Donadel-Claeyssens, MD, PhD, Jenny Goudemand, MD, PhD, Benoît Guillet, MD, PhD, Yves Gruel, MD, PhD, Valérie Roussel-Robert, MD, Fabienne Volot, MD, Thierry Calvez, MD, MSc

Blood (2011) 118 (21): 1213.

https://doi.org/10.1182/blood.V118.21.1213.1213

Published: 2011

Journal Articles

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Roseline d’Oiron, Jean Maurice Lavergne, Jenny Goudemand, Annie Borel-Derlon, Claude Guerois, Chantal Rothschild, Kathelijne Peerlinck, Herve Chambost, Natalie Stieltjes, the Belgian French MHAI Study Group

Blood (2004) 104 (11): 3088.

https://doi.org/10.1182/blood.V104.11.3088.3088

Published: 2004

Journal Articles

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development

Roseline d'Oiron, Jean-Maurice Lavergne, Renaud Lavend'homme, Abdellah Benhida, Jean-Claude Bordet, Claude Negrier, Kathelijne Peerlinck, Jos Vermylen, Jean-Marie Saint-Remy, Marc Jacquemin

Blood (2004) 103 (1): 155–157.

https://doi.org/10.1182/blood-2003-04-1321

Published: 2004

Journal Articles

Functional mapping of anti–factor IX inhibitors developed in patients with severe hemophilia B

Olivier D. Christophe, Peter J. Lenting, Ghislaine Cherel, Mariette Boon-Spijker, Jean-Maurice Lavergne, Ria Boertjes, Marie-Elisabeth Briquel, Arja de Goede-Bolder, Jenny Goudemand, Solange Gaillard, Roseline d'Oiron, Dominique Meyer, Koen Mertens

Blood (2001) 98 (5): 1416–1423.

https://doi.org/10.1182/blood.V98.5.1416

Published: 2001

Journal Articles

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor

Marc Jacquemin, Renaud Lavend'homme, Abdellah Benhida, Beatrijs Vanzieleghem, Roseline d'Oiron, Jean-Maurice Lavergne, Hans H. Brackmann, Rainer Schwaab, Thierry VandenDriessche, Marinee K. L. Chuah, Marc Hoylaerts, Jean Guy G. Gilles, Kathelijne Peerlinck, Jos Vermylen, Jean-Marie R. Saint-Remy

Blood (2000) 96 (3): 958–965.

https://doi.org/10.1182/blood.V96.3.958

Published: 2000

Journal Articles

Mutations in the fibrinogen Aα gene account for the majority of cases of congenital afibrinogenemia

Marguerite Neerman-Arbez, Philippe de Moerloose, Claire Bridel, Ariane Honsberger, Anni Schönbörner, Colette Rossier, Kathelijne Peerlinck, Ségolène Claeyssens, Donna Di Michele, Roseline d'Oiron, Marie Dreyfus, Monique Laubriat-Bianchin, Jacelyne Dieval, Stylianos E. Antonarakis, Michael A. Morris

Blood (2000) 96 (1): 149–152.

https://doi.org/10.1182/blood.V96.1.149

Published: 2000

Journal Articles

Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG

Alexandre Moreau, Sébastien Lacroix-Desmazes, Natalie Stieltjes, Evgueni Saenko, Srini V. Kaveri, Roseline D'Oiron, Yvette Sultan, Dorothea Scandella, Michel D. Kazatchkine

Blood (2000) 95 (11): 3435–3441.

https://doi.org/10.1182/blood.V95.11.3435

Published: 2000

Journal Articles

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor

Marc Jacquemin, Abdellah Benhida, Kathelijne Peerlinck, Benoı̂t Desqueper, Luc Vander Elst, Renaud Lavend'homme, Roseline d'Oiron, Rainer Schwaab, Marleen Bakkus, Kris Thielemans, Jean-Guy Gilles, Jos Vermylen, Jean-Marie Saint-Remy

Blood (2000) 95 (1): 156–163.

https://doi.org/10.1182/blood.V95.1.156

Published: 2000

NARROW

Subcutaneous Concizumab Prophylaxis in Patients with Hemophilia A or B with Inhibitors: Efficacy and Safety Results By Hemophilia Subtype from the Phase 3 Explorer7 Trial

How I manage pregnancy in women with Glanzmann thrombasthenia

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

The International Prospective Glanzmann's Thrombasthenia Registry (GTR) Special Issues in Children

The International Prospective Glanzmann's Thrombasthenia Registry (GTR). Special Issues in Women.

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

Environmental Risk Factors of Inhibitor in Mild/Moderate Hemophilia A Patients Included in the FranceCoag Network

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development

Functional mapping of anti–factor IX inhibitors developed in patients with severe hemophilia B

A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor

Mutations in the fibrinogen Aα gene account for the majority of cases of congenital afibrinogenemia

Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only